Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
11.01
UNCHANGED
Streaming Delayed Price
Updated: 9:37 AM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alvotech - Ordinary Shares
< Previous
1
2
3
4
5
Next >
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
April 18, 2023
From
The Schall Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 18, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 18, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Provides Update on Corporate Sustainability Framework
March 28, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 17, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
March 01, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023
From
Alvotech
Via
GlobeNewswire
Settlement of Alvotech Private Share Placement Completed
February 10, 2023
From
Alvotech
Via
GlobeNewswire
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
February 09, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 06, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 24, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Completes $137 Million Private Share Placement
January 23, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
January 13, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
January 11, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Completes $59.7 Million Private Placement
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
December 08, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
December 07, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Changes to its Leadership Team
December 01, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Secures Financing Facilities of Approximately $136 Million
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
November 14, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
November 10, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
October 27, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November
October 26, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
October 19, 2022
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.